GlassScriptPhysician profile
Umasankar Ramadoss
NPI 1962499806
$45,437.31
in general payments reported to CMS, 2019-2025
73 companies · $9,103 in 2025
The $9,103 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,950 · 2021: $6,866 · 2022: $4,473 · 2023: $4,270 · 2024: $2,052 · 2025: $9,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,126 · Food and Beverage: $6,023 · Travel and Lodging: $1,375 · Education: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,126.25 |
| Food and Beverage | $6,022.90 |
| Travel and Lodging | $1,374.88 |
| Education | $900.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $8,863.15 | 2019-2025 | Reblozyl, Pomalyst, Abecma |
| Astrazeneca Pharmaceuticals LP | $6,893.11 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Incyte Corporation | $5,399.69 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Karyopharm Therapeutics INC. | $2,670.07 | 2020-2025 | Xpovio |
| Fresenius Kabi USA, LLC | $2,250.00 | 2021 | |
| Janssen Biotech, INC. | $1,870.14 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $1,720.23 | 2021-2025 | Ojjaara, Blenrep |
| Aveo Pharmaceuticals, INC. | $1,557.00 | 2022-2025 | Fotivda |
| Blueprint Medicines Corporation | $1,199.77 | 2021-2024 | Ayvakit |
| Amgen INC. | $1,137.54 | 2019-2023 | Lumakras |
| Beigene, LTD. | $975.00 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $842.53 | 2019-2025 | |
| Seagen INC. | $814.18 | 2019-2025 | Tukysa, Padcev |
| Emd Serono, INC. | $784.96 | 2019-2025 | Bavencio |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $676.16 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Genentech USA, INC. | $598.02 | 2019-2025 | Tecentriq, Itovebi, Polivy |
| Abbvie INC. | $573.90 | 2019-2025 | |
| Pfizer INC. | $558.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $552.15 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $439.85 | 2019-2025 | Trodelvy |
| Lilly USA, LLC | $290.25 | 2020-2025 | Verzenio, Jaypirca |
| Genzyme Corporation | $284.32 | 2019-2024 | |
| Daiichi Sankyo INC. | $260.56 | 2020-2025 | Enhertu, Injectafer |
| Exelixis INC. | $244.02 | 2019-2024 | Cabometyx |
| Kite Pharma, INC. | $237.96 | 2019-2025 | Yescarta |
| Eisai INC. | $234.69 | 2020-2024 | |
| Array Biopharma INC | $219.98 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Rigel Pharmaceuticals, INC. | $207.45 | 2020-2024 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $206.69 | 2019-2025 | Zepzelca |
| Epizyme, INC. | $202.63 | 2020-2022 | |
| Sobi, INC | $168.50 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.15 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $119.46 | 2020-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $118.66 | 2020-2024 | Xospata, Xtandi, Padcev |
| Sanofi-Aventis U.S. LLC | $108.24 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $99.84 | 2019 | |
| Beigene USA, INC. | $80.32 | 2021-2025 | Tevimbra, Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.07 | 2019-2023 | Gilotrif |
| Takeda Pharmaceuticals U.S.A., INC. | $70.89 | 2019-2025 | Iclusig |
| Clovis Oncology, INC. | $70.48 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.04 | 2022-2023 | Libtayo |
| Servier Pharmaceuticals LLC | $67.11 | 2022-2023 | |
| Taiho Oncology, INC. | $57.53 | 2019-2022 | |
| Stemline Therapeutics INC. | $51.56 | 2023-2024 | Orserdu |
| Scilex Pharmaceuticals INC. | $48.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $45.71 | 2021 | |
| Dendreon Pharmaceuticals LLC | $45.62 | 2024 | Provenge |
| Beone Medicines USA, INC. | $42.63 | 2025 | Tevimbra, Brukinsa |
| Kaleo, INC. | $37.80 | 2019 | |
| Caris Mpi, INC. | $26.84 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $24.07 | 2020-2024 | Poteligeo |
| Pharmaessentia USA Corporation | $22.89 | 2025 | Besremi |
| Tesaro, INC. | $22.86 | 2019 | |
| Spectrum Pharmaceuticals INC. | $22.80 | 2025 | Rolvedon |
| Springworks Therapeutics, INC. | $21.57 | 2025 | Ogsiveo |
| Aimmune Therapeutics, INC. | $21.10 | 2025 | Zenpep |
| Immunogen, INC. | $18.13 | 2024 | Elahere |
| Foundation Medicine, INC. | $17.94 | 2023 | |
| Pharmacosmos Therapeutics INC. | $17.93 | 2024 | Cosela |
| Agios Pharmaceuticals, INC. | $17.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.20 | 2024 | Onivyde |
| Adaptive Biotechnologies Corporation | $17.19 | 2023 | Clonoseq |
| Puma Biotechnology, INC. | $17.13 | 2024 | |
| Novocure INC. | $16.49 | 2023 | Optune |
| Acceleron Pharma, INC. | $15.65 | 2021 | |
| Apellis Pharmaceuticals, INC. | $14.95 | 2024 | Empaveli |
| Coherus Oncology, INC. | $14.87 | 2024 | |
| Acrotech Biopharma INC. | $13.93 | 2022 | |
| Mirati Therapeutics, INC. | $13.76 | 2023 | Krazati |
| Teva Pharmaceuticals USA, INC. | $11.94 | 2020 | |
| Adc Therapeutics America, INC. | $11.40 | 2021 | |
| Secura Bio, INC. | $9.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umasankar Ramadoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.